What is the future of cholesterol lowering drugs in toxicology?
Advances in pharmacogenomics hold promise for more personalized approaches to managing cholesterol and minimizing toxicological risks. Understanding genetic factors that influence drug metabolism and susceptibility to side effects can lead to more individualized treatment plans. Additionally, ongoing research into new drug classes, such as inclisiran, which uses RNA interference to lower LDL cholesterol, may offer alternatives with different safety profiles.
